May 29, 2020
Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020
Apr 22, 2020
Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer
Mar 25, 2020
Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate Study
Dec 03, 2019
Nektar Appoints John Northcott as Chief Commercial Officer
Oct 02, 2019
Nektar Therapeutics Announces Five Abstracts Accepted for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Sep 30, 2019
Medicenna Presented Promising Preclinical Results from its IL-2 Superkine Platform at the 5th Annual International Cancer Immunotherapy Conference
Sep 26, 2019
Nature Communications Publishes Studies on Medicenna's IL-2 Superkine Platform
Jul 31, 2019
Medicenna Selects its Lead Immuno-Oncology Clinical Candidate, MDNA19, from its IL-2 Superkine Platform
Jun 20, 2019
Medicenna Presents New Preclinical Results For its IL-2 Superkine Platform, MDNA109
Apr 02, 2019
Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019
Apr 01, 2019
Vaccibody AS and Nektar Therapeutics Present New Preclinical Data from their Immuno-Oncology Collaboration at the American Association for Cancer Research (AACR) Annual Meeting 2019
Mar 01, 2019
Nektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting
Feb 27, 2019
Nektar Therapeutics Announces Several Preclinical Data Presentations for its Immuno-oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019
Nov 09, 2018
Synthorx to Present Preclinical Data for THOR-707, a "Not-Alpha" IL-2 Synthorin, for the Treatment of Solid Tumors at SITC 2018
Sep 27, 2018
Medicenna Solidifies Patent Protection For Long-Acting IL-2 Superkines